Healthcare Industry News:  Mylan 

Biopharmaceuticals Generics FDA

 News Release - August 30, 2006

Mylan Announces Tentative Approval for Fluoxetine Capsules, USP

PITTSBURGH, Aug. 30 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Fluoxetine Capsules, USP, 10mg and 20mg.

Fluoxetine Capsules are indicated for the treatment of premenstrual dysphoric disorder (PMDD). They are the AB-rated generic version of Eli Lilly and Company's Sarafem(TM) PulvulesŪ Capsules, which had annual U.S. sales of approximately $52 million for the 12 months ending June 30, 2006.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit

Source: Mylan Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.